On the stock market since 2017, it operates in the world of health and science. It has 90 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 7% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $99.3M a year. A small number, but proof the product has real buyers.
The average analyst price target is $7.00 — 94% above today’s price.
A loss of $2.4M against $99.3M in annual sales. And on top of that, sales fell from the year before.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, MEDXF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MEDXF is a high-risk stock — not yet profitable, and its future rides on its product catching on.